Recent developments in federal marijuana rescheduling center on the April 2026 Department of Justice order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while broader marijuana remains in Schedule I. A DEA administrative hearing on wider reclassification concluded in July 2026, with the chief administrative law judge now weighing testimony and post-hearing briefs filed in August. The DEA has argued in its final submission that marijuana meets criteria for accepted medical use and safety under supervision. A D.C. Circuit ruling on September 9 rejected efforts to stay the partial order amid ongoing litigation. Trader consensus on Polymarket reflects low implied probabilities for full rescheduling by year-end, citing the pending ALJ recommendation, potential court delays, and procedural hurdles before any DEA administrator decision.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$809,958 Vol.
September 30
2%
December 31
17%
$809,958 Vol.
September 30
2%
December 31
17%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Jul 31, 2026, 5:46 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent developments in federal marijuana rescheduling center on the April 2026 Department of Justice order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while broader marijuana remains in Schedule I. A DEA administrative hearing on wider reclassification concluded in July 2026, with the chief administrative law judge now weighing testimony and post-hearing briefs filed in August. The DEA has argued in its final submission that marijuana meets criteria for accepted medical use and safety under supervision. A D.C. Circuit ruling on September 9 rejected efforts to stay the partial order amid ongoing litigation. Trader consensus on Polymarket reflects low implied probabilities for full rescheduling by year-end, citing the pending ALJ recommendation, potential court delays, and procedural hurdles before any DEA administrator decision.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions